What Io Therapeutics does

Io Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Spring, Texas (Houston metro) that discovers and develops small molecule drugs targeting nuclear receptors, specifically Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs). The company is organized around three core pipeline assets: IRX4204, a selective RXR agonist that has been administered to over 100 patients across Phase I/II oncology and Parkinson's disease trials and is now positioned into psoriasis and HER2-positive breast cancer combination settings; IRX5183, a selective RARα agonist that completed Phase I in 36 patients with solid tumors and leukemias with activity in acute myeloid leukemia; and IRX5010, a preclinical RARγ agonist that promotes tumor-infiltrating T-lymphocyte activity and has shown combination potential with checkpoint inhibitors. Mechanistically, the compounds are positioned to induce ferroptosis in cancer cells, promote remyelination in neurodegenerative conditions, and modulate immune dysregulation in autoimmune disease, with demonstrated synergy when combined with lenalidomide, trastuzumab, anti-PD-L1 agents, and BCMA- or HER2-directed CAR-T therapies. The company holds an issued and pending patent estate covering IRX4204 across cancer, neurodegenerative, and autoimmune indications in the US and multiple international jurisdictions, plus issued US and European patents on IRX5183 for multiple myeloma, and operates through collaborations with Duke University, MD Anderson Cancer Center, Dartmouth College, and King's College London. As a pre-revenue company with 1–10 employees, Io Therapeutics has no commercial products; its future revenue model is pharmaceutical product sales upon regulatory approval distributed through wholesalers, specialty pharmacies, and direct-to-provider channels to oncology, neurology, and dermatology specialty practices.

Name

Io Therapeutics

Legal name

Io Therapeutics, Inc.

Website

https://io-therapeutics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Io Therapeutics is a privately held, clinical-stage biopharmaceutical company that discovers and develops small molecule retinoid and rexinoid drugs (IRX4204, IRX5183, IRX5010) targeting nuclear receptors for oncology, neurodegenerative, and autoimmune diseases.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Small molecule therapeutics
• Nuclear receptor drugs
• Oncology drug development
• Neurodegenerative therapeutics
• Autoimmune disease drugs

Headquarters

HQ city

Santa Ana

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue biopharmaceutical company. Revenue will be generated through sales of proprietary small molecule drugs upon regulatory approval. Target indications include HER2-positive breast cancer, Parkinson's disease, Alzheimer's disease, psoriasis, inflammatory arthritides, multiple myeloma, and acute myeloid leukemias.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Io Therapeutics discovers and develops retinoid and rexinoid small molecule drug candidates that selectively activate nuclear receptors (RARs and RXRs) to treat cancers, neurodegenerative diseases, and autoimmune diseases. Its lead asset IRX4204 is a selective RXR agonist that has been tested in over 100 patients across Phase I and II trials, while IRX5183 (RARα agonist) and IRX5010 (RARγ agonist) advance additional oncology and immuno-oncology programs.

Product overview

Io Therapeutics is discovering and developing a series of retinoid and rexinoid small molecules for the treatment of cancers, neurodegenerative diseases, and autoimmune diseases. The company's lead program is IRX4204 (RXR agonist) for HER2-positive breast cancer, Parkinson's disease, Alzheimer's disease, normal brain aging, psoriasis, and inflammatory arthritides. The second clinical stage program is IRX5183 (RARα agonist) for multiple myeloma and acute myeloid leukemias. IRX5010 (RAR gamma agonist) is in preclinical development for multiple cancer types. Additional compounds in discovery and preclinical development target cancer and neurodegenerative/autoimmune disease indications.

Differentiator

Problem solved

Functional benefit

Products and services

• IRX4204 A potent, highly selective Retinoid X Receptor (RXR) agonist small molecule drug with demonstrated anti-cancer, anti-neurodegenerative, and anti-autoimmune disease activities. It has been administered to over 100 patients in Phase I and II clinical studies under US INDs across indications including HER2-positive breast cancer, Parkinson's disease, Alzheimer's disease, psoriasis, and inflammatory arthritides. It features brain penetrance and once-per-day oral dosing.
• IRX5183 An orally bioavailable small molecule with a highly selective RARα agonist profile effective in animal models of acute myeloid leukemia and multiple myeloma. It has successfully completed Phase I clinical trials in 36 patients with solid tumors and leukemias, demonstrating activity in AML patients as monotherapy.
• IRX5010 A novel retinoic acid nuclear receptor gamma agonist that promotes development of tumor infiltrating T-lymphocytes and has anti-cancer activities through immune system stimulation rather than direct cytotoxic effects. It is effective in animal models of non-small cell lung cancer, triple-negative breast cancer, HER2+ breast cancer, colon cancer, and prostate cancer, and has shown combination effects with anti-PDL-1 checkpoint inhibitor.

Quantifiable outcome

• IRX4204 significantly delayed or prevented mammary tumor formation in triple-negative breast cancer mouse models with minimal toxicities
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Duke UniversitycoreStrategic or Co-development Partner · 25 March 2026Collaboration with Duke University scientists on research demonstrating the efficacy of IRX4204 in combination with lenalidomide against multiple myeloma. Studies showed that IRX4204 induces ferroptosis in myeloma cells and enhances therapeutic effects in preclinical models.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development Partner · 11 March 2026Collaboration with researchers at MD Anderson Cancer Center on preclinical studies of IRX4204 for breast cancer prevention. Research published in Cancer Prevention Research demonstrated that IRX4204 delayed or prevented tumor formation in triple-negative breast cancer mouse models.
• Dartmouth CollegecoreStrategic or Co-development PartnerAcademic collaboration with Professor Randy Noelle, co-founder of Io Therapeutics and Professor of Immunology and Microbiology at Dartmouth. Professor Noelle received a $7M Wellcome Trust Principal Research Fellowship Award to study the role of retinoids in autoimmune disease.
• King's College LondoncoreStrategic or Co-development PartnerAcademic collaboration with Professor Randy Noelle, who holds joint appointments at King's College London as Professor of Transplant Science and Immunotherapy.
• K&L Gates LLPminorImplementation/ SI/ Consulting PartnerLegal advisors providing general and intellectual property counsel. The firm prepared and prosecuted much of the Io Therapeutics patent estate.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Syros Pharmaceuticals: Clinical-stage biopharmaceutical company developing small molecule therapies targeting gene control, with RARα-agonist tamibarotene for oncology indications. Directly comparable to Io Therapeutics' IRX5183 RARα agonist program in AML/multiple myeloma.
• Reata Pharmaceuticals: Developed rexinoid/Nrf2 activator bardoxolone methyl for chronic kidney disease and neurological conditions, sharing nuclear-receptor-adjacent small molecule development approach with Io Therapeutics. Now part of Biogen, illustrating the strategic exit path for rexinoid-focused biopharma.
• Constellation Pharmaceuticals: Clinical-stage biopharmaceutical company developing small molecule oncology drugs (now acquired by MorphoSys). Comparable as a similarly-sized clinical-stage company with multiple small molecule programs in oncology.
• Syndax Pharmaceuticals: Clinical-stage immuno-oncology company developing small molecule combination therapies including HDAC inhibitors and immune modulators. Comparable in pursuing immune-modulating small molecules for oncology combination strategies.
• Madrigal Pharmaceuticals: Clinical-stage biopharma developing small molecule therapies targeting specific nuclear hormone receptors (THR-β agonist resmetirone). Directly comparable mechanism and clinical development model to Io Therapeutics' nuclear receptor agonist approach.

Emerging players

• Keros Therapeutics: Clinical-stage biotech developing small molecules targeting the TGF-β superfamily for hematological and musculoskeletal disorders. Comparable as a small molecule biopharma advancing multiple programs through clinical development.
• Denali Therapeutics: Clinical-stage biotech developing small molecule and biologic therapies for neurodegenerative diseases including Parkinson's and Alzheimer's. Comparable for Io Therapeutics' neurodegenerative disease programs targeting brain-penetrant small molecules.

Broad incumbents

• Biogen: Large biopharmaceutical company with leading multiple sclerosis franchise and acquired Reata Pharmaceuticals for its rexinoid program. Comparable as potential strategic acquirer/partner for Io Therapeutics' neurodegenerative and rexinoid assets.
• Roche: Global pharmaceutical company with leading HER2+ breast cancer franchise (Herceptin/Perjeta/Kadcyla) and large neurodegenerative pipeline. Highly relevant as potential combination-therapy partner or acquirer given Io Therapeutics' HER2 synergy data.
• Bristol-Myers Squibb: Major oncology biopharma with multiple myeloma franchise (Revlimid/lenalidomide, BCMA CAR-T ide-cel) and autoimmune portfolio. Highly relevant as combination-therapy partner for IRX4204 given demonstrated synergy with both lenalidomide and BCMA CAR-T.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/io-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Io Therapeutics